H&N Cancer Market to Reach $2.6B by 2032
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
